IPI-145 (INK1197) is a novel and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM. IPI 145 is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, PI3K delta/gamma inhibitor IPI 145 prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal, non-neoplastic cells is minimally or not affected which would result in a more favorable side effect profile. [1][2]
Chemical Information
|
Molecular Weight (WM):
|
416.86
|
|
Formula:
|
C22H17ClN6O
|
|
CAS No:
|
1201438-56-3
|
|
Purity:
|
≥ 98%
|
|
Synonyms:
|
INK-1197, INK 1197
|
|
|
2 years -20℃ Powder
|
|
Stability:
|
2 weeks -4℃ in DMSO
|
|
|
2 months -80℃ in DMSO
|
|
Quality control data:
|
|
Quality control by 1H-NMR, 13C-NMR, HPLC and LCMS.
|
|
Product will be shipped with supporting analytical data.
|
PLEASE KEEP THE PRODUCT UNDER -20℃ FOR LONG-TERM STORAGE.
NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.
Apoptosis
Telomerase
Chinese
Deutsch
Espanol
Francais
Italiano
Portugues
Japanese
Korean
Arabic
Russian